FIGURE 7.

The effects of UCL1684 and vernakalant on action potential and Ca²⁺ transient of hiPSC‐aCMs and ‐vCMs. Representative V_m and Ca²⁺ transients illustrating the effects of A, UCL1684 and B, vernakalant on hiPSC‐aCMs and ‐vCMs. Higher drug doses are presented by a progressively darker shade. The effects of C, AVE0118 and D, UCL1684 on normalized (percent change from predrug baseline) action potential duration (APD) and Ca²⁺ transient duration (CaTD); both parameters being measured at 20%, 50%, and 80%. Dashed line is the normalized predrug control presented as 0% change. n = 6 from six independent differentiation batches. hiPSC‐derived atrial cardiomyocytes (aCMs) are shown in red while hiPSC‐derived ventricular cardiomyocytes (vCMs) are presented in blue. Data are presented as mean ± SEM. Drug effects were compared between hiPSC‐aCMs and ‐vCMs using unpaired t test at each dose, *P < .05, **P < .001, ***P < .001. NS stands for not significant